SourceOne Global Partners (Chicago) organized an open-label trial on 84 hypercholestermic men and women to see if a combination of polymethoxylated flavones and tocotrienols (Chollestrinol HP) could reduce CRP levels.
Clinical science suggests that C-reactive protein (CRP) is a suitable biomarker for assessing risk of cardiovascular disease and inflammation. With this in mind, SourceOne Global Partners (Chicago) organized an open-label trial on 84 hypercholestermic men and women to see if a combination of polymethoxylated flavones and tocotrienols (Chollestrinol HP) could reduce CRP levels.
After 12 weeks, all patients reportedly saw decreases in high-sensitivity CRP by an average of 2.4 mg/l to 1.4 mg/l. Twenty-one patients reportedly responded even better, averaging a drop from 3.6 mg/l to 1.7 mg/l.
Andreas Supersaxo, R&D director for Vesifact (Baar, Switzerland) and a member of SourceOne’s scientific board, notes the significance: “The American Heart Association has designated a CRP concentration of less than 1 mg/l as representing low risk for cardiovascular disease, whereas concentrations of 1.0 to 3.0 mg/l and greater than 3.0 mg/l have been designated as representing average risk and high risk, respectively.”
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.